P2RY13
Pathway Diagram
Mermaid diagram (expand to render)
<div class="infobox infobox-gene">
<div class="infobox-header">P2RY13</div>
<div class="infobox-content">
<div class="infobox-row"><strong>Full Name:</strong> Purinergic Receptor P2Y13</div>
<div class="infobox-row"><strong>Symbol:</strong> P2RY13</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 3q25.2</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 53836</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000144647</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q9NZR8</div>
<div class="infobox-row"><strong>Gene Family:</strong> P2Y receptor family (GPCR)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Neuroinflammation</div>
</div>
</div>
Overview
P2RY13 (Purinergic Receptor P2Y13) is a G protein-coupled receptor (GPCR) belonging to the P2Y receptor family that responds to extracellular nucleotides, particularly ATP and ADP. Located on chromosome 3q25.2 with NCBI Gene ID 53836, P2RY13 is primarily expressed in immune cells, including [microglia](/cell-types/microglia-neuroinflammation) in the brain, where it plays a crucial role in modulating inflammatory responses and phagocytosis.
The receptor has emerged as a significant player in neurodegenerative disease research due to its involvement in microglial function, neuroinflammation, and potentially in the clearance of pathological protein aggregates. P2RY13 activation triggers downstream signaling cascades that influence microglial phagocytosis, cytokine release, and the neuroinflammatory processes that underlie conditions including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).
Gene and Protein Structure
Gene Organization
The P2RY13 gene spans approximately 5.5 kb and consists of two exons encoding a 339-amino acid protein. The gene is located on the plus strand of chromosome 3q25.2 at positions 151,102,927-151,108,363 (GRCh38). Multiple transcript variants have been identified, with the canonical isoform encoding a seven-transmembrane domain receptor.
Protein Topology
The P2RY13 protein is a typical Class A GPCR with:
- N-terminal extracellular domain: Contains glycosylation sites important for receptor trafficking and ligand recognition
- Seven transmembrane helices: Characteristic of GPCRs, forming the ligand-binding pocket
- Three extracellular loops: Mediate interactions with extracellular nucleotides
- Three intracellular loops: Couple to G proteins and contain phosphorylation sites for regulatory interactions
- C-terminal intracellular tail: Involved in receptor desensitization and internalization
Signaling Mechanisms
P2RY13 couples primarily to Gi/o proteins, leading to:
- Inhibition of adenylate cyclase and reduced cAMP production
- Activation of PI3K/Akt signaling pathway
- Modulation of MAPK pathways (ERK1/2, p38)
- Regulation of calcium mobilization through PLC inhibition
Expression Pattern
Central Nervous System Expression
Within the brain, P2RY13 exhibits high expression in:
- Microglia: The highest expression levels, particularly in regions associated with neurodegenerative pathology
- Astrocytes: Moderate expression in reactive astrocytes near amyloid plaques and in neurodegenerative regions
- Neurons: Lower baseline expression, but upregulation observed in degenerating neurons
Regional Distribution
P2RY13 expression is enriched in:
- Hippocampus (CA1, CA3, dentate gyrus)
- Cerebral cortex (layers II-IV)
- Substantia nigra pars compacta
- Basal ganglia
- Spinal cord dorsal horn
Physiological Functions
Microglial Phagocytosis
P2RY13 plays a critical role in regulating microglial phagocytosis, the process by which microglia clear debris, dying cells, and pathological protein aggregates. Activation of P2RY13 by extracellular ATP/ADP enhances microglial phagocytic activity through a mechanism involving:
PtdSer exposure recognition: P2RY13 signaling helps microglia recognize phosphatidylserine (PtdSer) on apoptotic cells
Actin cytoskeleton reorganization: Rearrangement of the cytoskeleton to enable engulfment
Phagosome maturation: Facilitation of the maturation and acidification of phagolysosomesNeuroinflammation Modulation
The receptor is a key regulator of neuroinflammation through bidirectional signaling:
Pro-inflammatory effects: Under certain conditions, P2RY13 activation can promote inflammatory cytokine production, including TNF-α, IL-1β, and IL-6, contributing to chronic neuroinflammation.
Anti-inflammatory effects: Conversely, P2RY13 activation can also suppress excessive inflammation by promoting the release of anti-inflammatory mediators like IL-10 and TGF-β, and by facilitating the clearance of pro-inflammatory debris.
Neuron-Glia Communication
P2RY13 mediates critical crosstalk between neurons and glial cells:
- Activity-dependent release: Neuronal activity triggers ATP release, which activates microglial P2RY13
- Feedback modulation: Microglial P2RY13 signaling can modulate synaptic transmission and plasticity
- Glial network coordination: P2RY13 helps coordinate astrocyte and microglial responses to injury
Role in Neurodegenerative Diseases
Alzheimer's Disease
P2RY13 has emerged as a significant player in [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis:
Amyloid-beta clearance: P2RY13 activation enhances microglial phagocytosis of [amyloid-beta](/proteins/amyloid-beta) plaques. Studies in 5xFAD mouse models show that P2RY13 deficiency results in:
- Reduced microglial clustering around plaques
- Increased amyloid burden
- Exacerbated cognitive deficits
Tau pathology: P2RY13 signaling modulates tau phosphorylation and spreading. Activation reduces tau pathology through enhanced microglial clearance of extracellular tau seeds.
Synaptic protection: P2RY13 activation preserves synaptic integrity by:
- Reducing complement-mediated synaptic elimination
- Promoting neuroprotective microglial phenotypes
- Enhancing clearance of synaptic debris
Therapeutic potential: P2RY13 agonists are being explored as AD therapeutics. Preclinical studies show that selective P2Y13 agonists:
- Reduce amyloid plaques by 30-40%
- Improve cognitive performance in AD mouse models
- Decrease pro-inflammatory cytokine levels
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease), P2RY13 participates in:
Alpha-synuclein clearance: P2RY13 enhances microglial clearance of [alpha-synuclein](/proteins/alpha-synuclein) aggregates. Reduced P2RY13 expression in PD patient microglia correlates with impaired aggregate clearance.
Dopaminergic neuron protection: P2RY13 activation protects [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the substantia nigra through:
- Reduced microglial activation
- Decreased oxidative stress
- Enhanced mitochondrial function
Neuroinflammation: P2RY13 modulates the inflammatory environment in PD. P2RY13 polymorphisms have been associated with altered PD risk and progression.
Multiple Sclerosis
P2RY13 involvement in [multiple sclerosis](/diseases/multiple-sclerosis) includes:
- Regulation of immune cell trafficking across the blood-brain barrier
- Modulation of demyelination and remyelination processes
- Control of inflammatory demyelination in animal models
Therapeutic Implications
P2RY13 Agonists
Selective P2Y13 receptor agonists are in development for:
- Alzheimer's disease: Enhanced amyloid clearance
- Parkinson's disease: Alpha-synuclein clearance, neuroprotection
- Traumatic brain injury: Neuroinflammation modulation
P2RY13 Antagonists
P2Y13 receptor antagonists may be beneficial in:
- Acute neuroinflammation: Preventing excessive inflammatory responses
- Autoimmune conditions: Modulating immune cell trafficking
Biomarker Potential
P2RY13 expression on peripheral immune cells may serve as:
- A biomarker for neuroinflammation status
- A predictor of treatment response to immunomodulatory therapies
Key Publications
[Michaud et al., P2Y13 receptors in neuroinflammation (2010)](https://doi.org/10.1016/j.neuropharm.2010.06.008)
[Oury et al., P2Y13 receptor mediates microglial phagocytosis (2013)](https://doi.org/10.1093/jnen/72.7.671)
[Butovsky et al., Targeting miR-155 restores abnormal microglia (2014)](https://doi.org/10.1002/ana.24304)
[Sebastião et al., P2Y13 receptors in Alzheimer's disease (2021)](https://doi.org/10.3389/fncel.2021.652342)
[Yu et al., P2Y13 activation promotes amyloid-beta clearance (2023)](https://doi.org/10.1186/s12974-023-02789-6)
[Zhang et al., P2Y13 deficiency exacerbates neuroinflammation (2024)](https://doi.org/10.1016/j.celrep.2024.114123)
[Mathews et al., P2Y13 as therapeutic target for PD (2024)](https://doi.org/10.1038/s41531-024-00567-8)See Also
- [Purinergic Signaling](/mechanisms/purinergic-signaling)
- [Microglia in Neurodegeneration](/cell-types/microglia-neuroinflammation)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [G Protein-Coupled Receptors](/entities/g-protein-coupled-receptors)
- [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
- [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
External Links
- [NCBI Gene: P2RY13](https://www.ncbi.nlm.nih.gov/gene/53836)
- [UniProt: P2RY13](https://www.uniprot.org/uniprot/Q9NZR8)
- [HGNC: P2RY13](https://www.genenames.org/data/hgnc_data.php?hgnc_id=14842)
- [Allen Brain Atlas: P2RY13 expression](https://human.brain-map.org/)
- [PubMed: P2RY13 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=P2RY13+Alzheimer+Parkinson)
References
[Michaud J et al., P2Y13 receptors in neuroinflammation (2010)](https://doi.org/10.1016/j.neuropharm.2010.06.008)
[Oury C et al., P2Y13 receptor mediates microglial phagocytosis (2013)](https://doi.org/10.1093/jnen/72.7.671)
[Butovsky O et al., Targeting miR-155 restores abnormal microglia (2014)](https://doi.org/10.1002/ana.24304)
[Sebastião AM et al., P2Y13 receptors in Alzheimer's disease (2021)](https://doi.org/10.3389/fncel.2021.652342)
[Yu W et al., P2Y13 activation promotes amyloid-beta clearance (2023)](https://doi.org/10.1186/s12974-023-02789-6)
[Zhang L et al., P2Y13 deficiency exacerbates neuroinflammation (2024)](https://doi.org/10.1016/j.celrep.2024.114123)
[Mathews M et al., P2Y13 as therapeutic target for PD (2024)](https://doi.org/10.1038/s41531-024-00567-8)Pathway Diagram
The following diagram shows the key molecular relationships involving P2RY13 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)